However, only approximately 20% of patients with HNSCC achieve a durable response to ICI treatment, indicating that most patients with HNSCC are resistant to PD1 blockade-based immunotherapy [11–13]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.